[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"relapsed-and-refractory\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:relapsed-and-refractory":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100608182","drug-eluting-bead-based-transarterial-chemoembolization-deb-tace-as-a-local-salvage-therapy-for-large-lesions-in-relapsed-and-refractory-diffuse-large-b-cell-lymphoma-100608182",false,"NCT07198230","Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma","Inclusion Criteria:\n\n* (1) Age 18 to 75 years; (2) Pathologically confirmed diffuse large B-cell lymphoma (DLBCL); (3) Recurrence or treatment resistance following multiple therapeutic regimens (e.g., chemotherapy, immunotherapy, targeted therapy), with at least one clearly defined bulky lesion (maximum diameter ≥5 cm or imaging evidence of bulky lesion); (4) Imaging studies (CT, MRI, or PET-CT) confirm rich blood supply to the lesion, making it suitable for transarterial interventional therapy; (5) History of favorable response to doxorubicin-based agents during prior systemic therapy; (6) ECOG performance status ≤ 2; (7) Blood counts, hepatic and renal function, and coagulation parameters meet the following criteria:\n\n  * Platelet count ≥ 30 × 10\\^9\u002FL;\n  * Total bilirubin ≤ 1.5 times the upper limit of normal (ULN);\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the ULN;\n  * Serum creatinine ≤ 2.5 times the upper limit of normal (ULN);\n  * Prothrombin time international normalized ratio (INR) ≤ 1.5. (8) The patient has previously undergone at least one DEB-TACE treatment at this institution.\n\nExclusion Criteria:\n\n* (1) Patients with severe cardiac, pulmonary, hepatic, or renal dysfunction, or other serious comorbidities rendering them unable to tolerate interventional therapy; (2) Patients with active or uncontrolled severe infections; (3) Patients with severe coagulation disorders or bleeding tendencies; (4) Pregnant or lactating women, or patients planning pregnancy during the study period; (5) Allergy or contraindications to drug-eluting microsphere materials or chemotherapy drugs; (6) Psychiatric disorders or cognitive impairment preventing treatment compliance and follow-up; (7) Other conditions deemed unsuitable for study participation by the investigator.","ALL","18 Years","75 Years",{"count":19,"type":20},10,"ESTIMATED","OBSERVATIONAL","Current exploration of local therapies for large Diffuse Large B-Cell Lymphoma (DLBCL) masses remains in its infancy. This study aims to retrospectively evaluate the safety, efficacy, and tolerability of Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) for treating recurrent and refractory DLBCL masses. It seeks to establish a novel local salvage treatment strategy for such patients while providing preliminary theoretical foundations and clinical data to support future large-scale, multicenter clinical trials.",[24,25,26],"Diffuse Large B-Cell Lymphoma","Relapsed and Refractory","Transarterial Chemoembolization","RECRUITING","2025-11-15",{"date":30,"type":31},"2025-11-18","ACTUAL",{"date":33,"type":31},"2025-03-01",{"date":35,"type":20},"2027-09-01",{"name":37,"class":38},"Ting YANG","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":39},"100566182","phase-2-large-fraction-radiation-therapy-combined-with-lenalidomide-and-glofitamab-in-refractory-relapsed-dlbcl-100566182","NCT06651853","Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL","The Efficacy and Safety of Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab Monoclonal Antibody in the Treatment of Refractory Relapsed Diffuse Large B-cell Lymphoma Patients","Inclusion Criteria:\n\n1. Written informed consent must be obtained before any trial-related procedures are implemented.\n2. Participants must be aged 18 or older, of any gender, with an expected survival period of more than 3 months.\n3. ECOG PS score must be between 0-3.\n4. Participants must have histopathologically confirmed diffuse large B-cell lymphoma.\n5. Patients who have failed first-line standard treatment (patients with relapsed disease \\\u003C 12 months or primary refractory disease, or relapsed disease \\> 12 months but are transplant-ineligible after 1 line of systemic therapy, or relapsed disease after 2+ lines of therapy). Participants with central nervous system metastasis can be included.\n6. Participants must not have received bispecific antibody therapy in the past.\n7. B-cell non-Hodgkin's lymphoma must have at least one measurable lesion according to RECIST1.1 criteria.\n8. Participants must have sufficient organ function, meeting the following:\n\n   laboratory criteria: (1) Total bilirubin ≤1.5× upper limit of normal (ULN); (2) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5× ULN; (3) Blood creatinine ≤1.5× ULN and creatinine clearance rate (calculated using the Cockcroft-Gault formula) ≥60 ml\u002Fmin; (4) Good coagulation function, defined as an international normalized ratio (INR) or prothrombin time (PT) ≤1.5 times ULN.\n9. For women of childbearing potential, a urine or serum pregnancy test must be conducted within 3 days before the first administration of the study drug (Day 1 of Cycle 1) and the results must be negative. If the results of the urine pregnancy test cannot be confirmed as negative, a blood pregnancy test is required. Non-childbearing women are defined as those who have been menopausal for at least 1 year, or who have undergone surgical sterilization or hysterectomy.\n10. If there is a risk of pregnancy, all participants (both male and female) must use contraception with an annual failure rate of less than 1% throughout the treatment period and for 120 days after the last administration of the study drug (or 180 days after the last chemotherapy administration).\n\nExclusion Criteria:\n\n1. B-cell non-Hodgkin's lymphoma with loss of CD20 expression.\n2. Acute or chronic active Hepatitis B or C infection, Hepatitis B virus (HBV) DNA\\>2000IU\u002Fml or 104 copies\u002Fml; Hepatitis C virus (HCV) RNA\\>103 copies\u002Fml; simultaneous positivity for Hepatitis B surface antigen (HbsAg) and anti-HCV antibody.\n3. Participants have received anti-hematologic malignancy treatment within 2 weeks before the start of treatment or within 5 half-lives of the drug, whichever is longer.\n4. Bone marrow insufficiency defined by platelet count \\\u003C30 x 109\u002FL or absolute neutrophil count \\\u003C1.0 x 109\u002FL.\n5. Participants with clinically significant pulmonary disease, including (1) participants with chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) \\\u003C50% of the predicted normal value. Note that participants suspected of having COPD need to undergo an FEV1 test, and if FEV1\\\u003C50% of the predicted normal value, the participant must be excluded. (2) Participants with moderate or severe persistent asthma in the past 2 years, or currently have any category of uncontrolled asthma. (Note that participants currently with controlled intermittent asthma or controlled mild persistent asthma can participate in this study).\n6. Uncontrolled hypertension, with systolic blood pressure \\>150mmHg or diastolic blood pressure \\>90mmHg after optimal medical treatment, history of hypertensive crisis or hypertensive encephalopathy.\n7. Symptomatic congestive heart failure (New York Heart Association class II-IV). Symptomatic or poorly controlled arrhythmias. History of congenital long QT syndrome or a corrected QTc \\>500ms (calculated using the Fridericia method) at screening.\n8. Large fraction radiation therapy received within 4 weeks prior to the first treatment. For patients who received radiation therapy more than 4 weeks before the first treatment, all the following conditions must be met to be included: there are currently no radiation-related toxic reactions, no need to take glucocorticoids, excluding radiation pneumonia, radiation hepatitis, radiation enteritis, etc.\n9. Patients who have difficulty swallowing oral medications.\n10. Past and current history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-related pneumonia, severe impairment of lung function, and other lung diseases.\n11. Human immunodeficiency virus (HIV) infection (HIV 1\u002F2 antibody positive), known syphilis infection.\n12. Presence of unhealed wounds, fractures, gastric and duodenal ulcers, persistent fecal occult blood positivity, ulcerative colitis, etc., or other conditions that the investigator determines may cause gastrointestinal bleeding or perforation.\n13. Active or poorly controlled severe infection. Severe infection within 4 weeks before the first administration, including but not limited to hospitalization for complications of infection, sepsis, or severe pneumonia.\n14. Major surgical treatment or significant traumatic injury received within 4 weeks before the first administration.\n15. Traditional Chinese medicine with anti-tumor indications received within 2 weeks before the first administration.\n16. Known allergy to any component of bispecific antibodies or GM-CSF formulations.\n17. Treatment in another clinical trial within 4 weeks before the first administration.\n18. Pregnant or breastfeeding female patients.\n19. Presence of any active autoimmune disease or history of autoimmune disease (such as but not limited to: autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, nephritis; participants who need bronchodilators for medical intervention for asthma cannot be included); but the following patients are allowed to participate: vitiligo, psoriasis, alopecia, well-controlled type I diabetes that does not require systemic treatment, and hypothyroidism with normal thyroid function through replacement therapy.\n20. Other acute or chronic diseases, mental illnesses, or abnormal laboratory test values that may lead to the following results: increase the risk associated with study participation or administration of the study drug, or interfere with the interpretation of study results, and according to the investigator's judgment, the patient is deemed ineligible to participate in this study.",{"count":48,"type":20},22,"INTERVENTIONAL",[51],"PHASE2","To prospectively evaluate the efficacy and safety of large fraction radiation therapy combined with granulocyte-macrophage colony-stimulating factor, lenalidomide, and glofitamab monoclonal antibody in the treatment of refractory relapsed diffuse large B-cell lymphoma patients",[54,25],"Diffuse Large B-cell Lymphoma","2025-07-19",{"date":57,"type":31},"2025-07-23",{"date":59,"type":31},"2024-10-21",{"date":61,"type":20},"2028-07-30",{"name":63,"class":38},"The First Affiliated Hospital of Xiamen University",{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":15,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":49,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":39},"100384232","early-phase-1-a-study-of-cd20cd22-targeted-car-t-cell-therapy-for-relapsed-or-refractory-lymphoid-malignancies-100384232","NCT04283006","A Study of CD20\u002FCD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies","Criteria:\n\nInclusion Criteria:\n\nInclusion criteria applicable to ALL only:\n\n1. Male or female aged ≥ 3 and \\\u003C70 years old;\n2. Histologically confirmed diagnosis of CD19+ B-ALL per the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Lymphoblastic Leukemia (2016.v1);\n3. Relapsed or refractory CD19+ B-ALL (meeting one of the following conditions):\n\n   1. CR not achieved after standardized chemotherapy;\n   2. CR achieved following the first induction, but CR duration is ≤ 12 months;\n   3. Ineffective after first or multiple remedial treatments;\n   4. 2 or more recurrences;\n4. The number of primordial cells (lymphoblast and prolymphocyte) in bone marrow is \\>5% (morphology) and\u002For \\>1% (Flow cytometry);\n5. Philadelphia-chromosome-negative (Ph-) patients; or Philadelphia-chromosome- positive (Ph+) patients who cannot tolerate TKI treatments or do not respond to 2 TKI treatments;\n\nInclusion criteria applicable to NHL only:\n\n1. Male or female aged ≥ 18 and \\\u003C70 years old;\n2. Histologically confirmed diagnosis per WHO Classification Criteria for Lymphocytic Tumors 2016, including DLBCL(NOS), follicular lymphoma, Chronic lymphoblastic leukemia\u002Fsmall lymphoblastic lymphoma transforms DLBCL, PMBCL and high grade B cell lymphoma;\n3. Relapsed or refractory DLBCL (meeting one of the following conditions):\n\n   1. No remission or recurrence after receiving second-line or above second-line chemotherapy;\n   2. Primary drug resistance;\n   3. Recurrence after autologous hematopoietic stem cell transplantation;\n4. According to Lugano 2014, there should be at least one evaluable tumor lesion.\n\nApplicable standards for ALL and NHL:\n\n1. HLA antibody(-) or HLA antibody(+) and HLA donor specific antibody(DSA)(-);\n2. total bilirubin ≤ 51umol\u002FL, ALT and AST ≤ 3 times of upper limit of normal, creatinine ≤ 176.8umol\u002FL;\n3. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥ 50%;\n4. No active infection in the lungs, blood oxygen saturation by sucking air is ≥ 92%;\n5. Estimated survival time ≥ 3 months;\n6. ECOG performance status 0 to 2;\n7. Patients or their legal guardians volunteer to participate in the study and sign the informed consent.\n\nExclusion Criteria:\n\n1. patients with extramedullary lesions, except those with CNSL (CNS-1) under effective control (for ALL patients only);\n2. Confirmed diagnosis of lymphoblastic crisis of chronic myeloid leukemia, Burkitt's leukemia\u002Flymphoma per WHO Classification Criteria (for ALL patients only);\n3. Patients with hereditary syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome (for ALL patients only);\n4. Patients with intracranial extralateral lesions (cerebrospinal fluid tumor cells and\u002For intracranial lymphoma invasion shown by MRI) (for NHL patients only) ;\n5. Extensive involvement of gastrointestinal lymphoma (for NHL patients only);\n6. Radiotherapy, chemotherapy and monoclonal antibody within 1 week before screening;\n7. Have a history of allergy to any of the components in the cell products;\n8. Prior treatment with any CAR T cell product or other genetically-modified T cell therapies;\n9. According to the New York heart association (NYHA) cardiac function classification criteria, Subjects with grade III or IV cardiac insufficiency;\n10. Myocardial infarction, cardioangioplasty or stenting, unstable angina pectoris, or other severe cardiac diseases within 12 months of enrollment;\n11. Severe primary or secondary hypertension of grade 3 or above (WHO Hypertension Guidelines, 1999);\n12. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;\n13. History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic diseases;\n14. Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis).\n15. Indwelling catheters in vivo (e.g. percutaneous nephrostomy, Foley catheter, bile duct catheter, or pleural\u002Fperitoneal\u002Fpericardial catheter). Ommaya storage, dedicated central venous access catheters such as Port-a-Cath or Hickman catheters are allowed;\n16. History of other primary cancer, except for the following conditions:\n\n    1. Cured non-melanoma after resection, such as basal cell carcinoma of the skin;\n    2. Cervical cancer in situ, localized prostate cancer, ductal cancer in situ with disease-free survival ≥ 2 years after adequate treatment;\n17. Patients with autoimmune diseases requiring treatment, patients with immunodeficiency or requiring immunosuppressive therapy;\n18. Patients with graft-versus-host disease (GVHD);\n19. Prior immunizations with live vaccine 4 weeks prior to screening;\n20. History of alcoholism, drug abuse or mental illness;\n21. If HBsAg positive at screening, HBV DNA copy number detected by PCR in patients with active hepatitis B \\> 1000 (if HBV DNA copy number≤1000, routine antiviral therapy is required after enrollment), as well as CMV, hepatitis C, syphilis infection;\n22. Concurrent therapy with systemic steroids within 1 week prior to screening, except for the patients recently or currently receiving inhaled steroids;\n23. Patients who have participated in any other clinical studies within 2 weeks prior to screening;\n24. Pregnant and breast-feeding women and the subjects who are fertile and unable to take effective contraceptive measures (regardless of the gender);\n25. Any situations that the investigator believes may increase the risk of patients or interfere with the results of study.","3 Years","70 Years",{"count":73,"type":20},100,[75],"EARLY_PHASE1","A Study of CD20\u002FCD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies.",[25,78],"Lymphoid Hematological Malignancies",[80,81,82],"lymphoid hematological malignancies","CAR T-cell therapy","CD20\u002FCD22","2020-08-20",{"date":85,"type":31},"2020-08-21",{"date":87,"type":31},"2018-05-23",{"date":89,"type":20},"2028-05-23",{"name":91,"class":38},"He Huang"]